Century Therapeutics (IPSC) Enterprise Value (2021 - 2026)

Century Therapeutics (IPSC) has reported Enterprise Value for 7 consecutive years, with -$134.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Enterprise Value rose 18.36% year-over-year to -$134.8 million; the TTM figure through Mar 2026 stood at -$134.8 million (up 18.36% YoY), while the FY2025 annual figure was -$168.6 million, up 10.96% from the prior year.
• Enterprise Value climbed to -$134.8 million in Q1 2026 per IPSC's latest filing, from -$168.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$132.7 million in Q3 2025 and bottomed at -$378.8 million in Q2 2022.
• Historically, Enterprise Value has averaged -$217.3 million across 5 years, with a median of -$189.3 million in 2024.
• Annual changes were most pronounced in 2022 — Enterprise Value tumbled 41.56% — and 2023, when it surged 58.71%.
• Century Therapeutics' Enterprise Value stood at -$315.5 million in 2022, then soared by 45.25% to -$172.7 million in 2023, then declined by 9.58% to -$189.3 million in 2024, then rose by 10.96% to -$168.6 million in 2025, then grew by 20.02% to -$134.8 million in 2026.
• Business Quant data shows IPSC's Enterprise Value at -$134.8 million in Q1 2026, -$168.6 million in Q4 2025, and -$132.7 million in Q3 2025.